Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | ACP1 | P24666 | 1/20 | 0.47 |
| ▸ | OGG1 | O15527 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093851 | 0.89 | ADORA3 (0.57) | ADORA3ADORA2AL3MBTL1HTTADORA1 | |
| SCHEMBL1093673 | 0.85 | ADORA3 (0.53) | ADORA3ADORA2AL3MBTL1HTTADORA1 | |
| SCHEMBL1093235 | 0.77 | ADORA3 (0.45) | ADORA3ADORA1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1093307 | 0.75 | L3MBTL1 (0.49) | ADORA3ADORA2AL3MBTL1HTTADORA1 | |
| SCHEMBL2170493 | 0.75 | MEN1 (0.43) | ADORA3ADORA2AHTTKDM4ELMNA | |
| SCHEMBL29042737 | 0.75 | NPC1 (0.47) | ADORA3ADORA2AL3MBTL1HTTNPC1 | |
| SCHEMBL2170815 | 0.72 | EPHX1 (0.53) | ADORA3HTTNPC1RAB9ALMNA | |
| SCHEMBL1093380 | 0.72 | TP53 (0.42) | ADORA3ADORA2AADORA1LMNASMN1; SMN2 | |
| SCHEMBL2346833 | 0.71 | TSHR (0.46) | ADORA3ADORA2AHTTKDM4ERAB9A | |
| SCHEMBL1093355 | 0.70 | ADORA3 (0.44) | ADORA3ADORA2AADORA1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102164899-B | Substituted indazoles or tetrahydroindazoles as FXR modulators against dyslipidemia and related diseases | HOFFMANN LA ROCHE | 2014-11-26 | — | — | CN | disclosed |
| EP-2344459-B1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | HOFFMANN LA ROCHE (CH) | 2013-12-25 | — | — | EP | disclosed |
| EP-2346834-B1 | 3-AMINO-INDAZOLE OR 3-AMINO-4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-8153663-B2 | 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8008505-B2 | Indazole or 4,5,6,7-tetrahydro-indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | disclosed |
| CN-102164899-A | 2, 3-substituted indazoles or 4,5,6, 7-tetrahydro-indazoles as FXR modulators against dyslipidemia and related diseases | HOFFMANN LA ROCHE | 2011-08-24 | — | — | CN | disclosed |
| CN-102164900-A | 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives | HOFFMANN LA ROCHE | 2011-08-24 | — | — | CN | disclosed |
| EP-2346834-A1 | 3-AMINO-INDAZOLE OR 3-AMINO-4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| EP-2344459-A1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | F. Hoffmann-La Roche AG (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010034657-A1 | 3-AMINO-INDAZOLE OR 3-AMINO-4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010034649-A1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-01 | — | — | WO | disclosed |
| US-20100076027-A1 | INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | disclosed |
| US-20100076026-A1 | 3-AMINO-INDAZOLE OR 3-AMINO-4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076026-A1 | 3-AMINO-INDAZOLE OR 3-AMINO-4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | NR1H4, SLC10A2, SLC10A1 | ADORA3 11/4885ADORA2A 380/4885L3MBTL1 4388/4885 |
| US-20100076027-A1 | INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | NR1H4, ABCB11, FXR1 | ADORA3 35/4885ADORA2A 501/4885L3MBTL1 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.